CA2964377A1 - Nargenicin compounds and uses thereof as antibacterial agents - Google Patents

Nargenicin compounds and uses thereof as antibacterial agents Download PDF

Info

Publication number
CA2964377A1
CA2964377A1 CA2964377A CA2964377A CA2964377A1 CA 2964377 A1 CA2964377 A1 CA 2964377A1 CA 2964377 A CA2964377 A CA 2964377A CA 2964377 A CA2964377 A CA 2964377A CA 2964377 A1 CA2964377 A1 CA 2964377A1
Authority
CA
Canada
Prior art keywords
6alkyl
arya
ring
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2964377A
Other languages
English (en)
French (fr)
Inventor
Katherine Young
David B. Olsen
Sheo B. Singh
Jing Su
Robert R. Wilkening
James M. Apgar
Dongfang Meng
Dann Parker
Mihir Mandal
Lihu Yang
Ronald E. Painter
Qun Dang
Takao Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2964377A1 publication Critical patent/CA2964377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2964377A 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents Abandoned CA2964377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/089204 2014-10-22
PCT/CN2014/089204 WO2016061772A1 (en) 2014-10-22 2014-10-22 Nargenicin compounds and uses thereof as antibacterial agents
PCT/US2015/056627 WO2016064982A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Publications (1)

Publication Number Publication Date
CA2964377A1 true CA2964377A1 (en) 2016-04-28

Family

ID=55760063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964377A Abandoned CA2964377A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Country Status (11)

Country Link
US (2) US9944654B2 (https=)
EP (1) EP3209667B1 (https=)
JP (1) JP2017533200A (https=)
KR (1) KR20170070197A (https=)
CN (1) CN107108646A (https=)
AU (1) AU2015335992A1 (https=)
BR (1) BR112017008101A2 (https=)
CA (1) CA2964377A1 (https=)
MX (1) MX2017005271A (https=)
RU (1) RU2017117253A (https=)
WO (2) WO2016061772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148883A (en) 1977-08-18 1979-04-10 Pfizer Inc. Antibiotics produced by new species of nocardia
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
US4436747A (en) 1982-10-21 1984-03-13 Pfizer Inc. Nargenicin C1
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1
ES2258234T3 (es) 2002-08-12 2006-08-16 PHARMACIA & UPJOHN COMPANY LLC N-aril-2-oxazolidinonas y sus derivados.
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
MXPA05005522A (es) 2002-11-28 2005-07-25 Astrazeneca Ab Oxazolidinonas como agentes antibacterianos.
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
WO2007133803A2 (en) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
KR101040468B1 (ko) 2008-02-29 2011-06-09 조선대학교산학협력단 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도
KR101022564B1 (ko) 2008-12-19 2011-03-16 조선대학교산학협력단 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물
WO2011139832A2 (en) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Also Published As

Publication number Publication date
CN107108646A (zh) 2017-08-29
KR20170070197A (ko) 2017-06-21
EP3209667A1 (en) 2017-08-30
RU2017117253A (ru) 2018-11-23
EP3209667A4 (en) 2018-06-06
JP2017533200A (ja) 2017-11-09
RU2017117253A3 (https=) 2019-04-16
AU2015335992A1 (en) 2017-04-20
US10144741B2 (en) 2018-12-04
WO2016064982A1 (en) 2016-04-28
EP3209667B1 (en) 2025-03-19
US9944654B2 (en) 2018-04-17
WO2016061772A1 (en) 2016-04-28
MX2017005271A (es) 2017-08-15
US20180186808A1 (en) 2018-07-05
BR112017008101A2 (pt) 2018-02-20
US20170305924A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
AU2017228870B2 (en) Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
AU2014268477A1 (en) Compounds for treatment of drug resistant and persistent tuberculosis
CN110003253A (zh) 三环苯并氧杂硼杂环戊烯化合物及其用途
CN107531730B (zh) 4-取代苯并氧杂硼杂环戊烯化合物及其用途
JP2021501756A (ja) 抗菌性化合物
EP2941428A1 (en) 4-pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (plk1) for the treatment of cancer and their use for the treatment of bacterial infections
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
US10144741B2 (en) Nargenicin compounds and uses thereof as antibacterial agents
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
JP2020523340A (ja) 環縮合チアゾリノ２−ピリドン、それらの調製方法、ならびにグラム陽性菌が関与する疾患の治療および／または予防におけるそれらの使用
WO2018175185A1 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
UA129060C2 (uk) Сполуки і способи їхнього застосування як антибактеріальних агентів
CA2884909A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
CN111527093B (zh) 抗菌杂环化合物及其合成
US20250188092A1 (en) Rifamycin analogs
RU2794494C2 (ru) Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220112